Business
Nasus Pharma CEO Issues 2025 Letter to Shareholders
TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today issued a letter to its shareholders from its Chief Executive Officer, Dan Teleman. Dear Shareholders, 2025 has been a transformational year for Nasus Pharma. We’ve made considerable progress building a strong, focused company w
About this update from Nasus Pharma Ltd.
[{"type":"image","alt":"Nasus Pharma, Ltd.","displaySize":"","headline":null,"caption":"Nasus Pharma, Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":241,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/quoV9o_G7y0qGuyE83dEZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f80d312befe1c63984fc7bf025e58d6d","width":241,"height":136}},"lazy":false},{"type":"text","content":"TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today issued a letter to its shareholders from its Chief Executive Officer, Dan Teleman.","length":375,"tagName":"p"},{"type":"text","content":"Dear Shareholders, 2025 has been a transformational year for Nasus Pharma. We’ve made considerable progress building a strong, focused company with significant clinical impact, by developing drug delivery products based on our proprietary Nasax powder technology, which has the potential to enhance intranasal drug absorption for improved outcomes.","length":348,"tagName":"p"},{"type":"text","content":"We began 2025 by presenting integrated data from two early clinical trials of NS002, our investigational intranasal epinephrine powder formulation, designed to address limitations of injectable Epinephrine, developed as a needle-free, easy-to-administer alternative to traditional epinephrine autoinjectors. The positive results show NS002 has demonstrated the potential for faster and higher absorption of epinephrine in a clinic setting. As anaphylaxis represents a time-critical medical emergency, faster epinephrine delivery can make the difference between life and death.","length":576,"tagName":"p"},{"type":"text","content":"To progress towards fulfilling our mission to innovate the field of life-saving medications, we successfully completed our initial public offering in August 2025, raising $10 million in gross proceeds and strengthening Nasus Pharma’s financial position.","length":253,"tagName":"p"},{"type":"text","content":"We have carried this positive momentum forward by advancing NS002’...